Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review
Pingjiao Chen,Jingyao Liang,Changxing Li,Qian Li,Wenyan Liu,Junhui Zhu,Weifeng Chen,Xibao Zhang
DOI: https://doi.org/10.2147/ccid.s446369
2024-01-06
Clinical Cosmetic and Investigational Dermatology
Abstract:Pingjiao Chen, 1, &ast Jingyao Liang, 2, 3, &ast Changxing Li, 1 Qian Li, 2, 3 Wenyan Liu, 2, 3 Junhui Zhu, 2, 3 Weifeng Chen, 2, 3 Xibao Zhang 2, 3 1 Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China; 2 Institute of Dermatology, Guangzhou Medical University, Guangzhou, 510095, People's Republic of China; 3 Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, 510095, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xibao Zhang, Department of Dermatology Guangzhou Institute of Dermatology, 56 Hengfu Road, Guangzhou, 510095, People's Republic of China, Tel +8620-83593476, Email Janus kinase (JAK) inhibitors are increasingly being used in dermatology due to their broad potential in managing both local and systemic inflammation. More recently, abrocitinib, an oral JAK 1 inhibitor, has shown promising clinical efficacy in the treatment of various skin disorders beyond moderate to severe atopic dermatitis (AD). We firstly presented three cases, each with diagnosis of pyoderma gangrenosum (PG), livedoid vasculopathy (LV), or hidradenitis suppurativa (HS), and conducted a comprehensive scoping review of the available literature on the use of abrocitinib in the treatment of diverse skin disorders. We summarized a total of 16 skin disorders, including our cases. The results indicated that abrocitinib, whether used as monotherapy or in combination with other treatments, was effective and well-tolerated in these disorders. These findings expanded the range of diseases for which abrocitinib may serve as an alternative therapeutic choice. Keywords: JAK inhibitors, abrocitinib, atopic dermatitis, pyoderma gangrenosum, livedoid vasculopathy, hidradenitis suppurativa The Janus kinase (JAK) family is composed of four types of cytoplasmic tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which mediate signal transduction from cell surface receptors to the nucleus. 1 The JAK pathways play a crucial role in response to over 50 inflammatory cytokines and are also involved in the differentiation of naive T cells into various types of immune cells, such as Th1, Th2, and Th17 cells. 2 These processes are closely associated with the pathogenesis of a wide range of inflammatory immune-mediated diseases, 3 making these conditions theoretically treatable by JAK inhibitors. Abrocitinib, inhibitor of JAK1, has recently shown promising results in the off-label treatment of some skin diseases associated with JAK activity, including alopecia areata (AA), and others. 4,5 Herein, we present a case series comprising three patients, each diagnosed with pyoderma gangrenosum (PG), livedoid vasculopathy (LV), or hidradenitis suppurativa (HS). These patients exhibited a favorable response to abrocitinib following inadequate outcomes with conventional therapies. Furthermore, we conducted a scoping review to provide a comprehensive summary of the current evidence concerning the off-label use of abrocitinib in dermatologic disorders. Patient A, a 16-year-old male, was admitted with growing, painful, ulcerative lesions that started as erythematous papules in perianal area for over 1 year. Physical examination showed multiple, painful swollen, centrally located deep ulcerations with massive purulent discharges (Figure 1Aa). A skin biopsy revealed extensive infiltration of lymphocytes and neutrophils, increased vascular proliferation and dilation (Figure 1Ab), which was consistent with the diagnosis of PG. The patient was prescribed doxycycline, isotretinoin, glucocorticoids, and cyclosporine A, but his symptoms continued to worsen. We initiated treatment with oral abrocitinib (100 mg daily) in combination with cyclosporine A (50 mg twice daily). The patient showed gradual improvement of his symptoms within one week (Figure 1Ac), and almost complete resolution of painful swelling and purulent discharges, significant reduction of the ulcer area and depth after four weeks (Figure 1Ad). Cyclosporine A was discontinued due to the good clinical response, and the patient continued to improve without any adverse events (AEs) over the 16-week follow-up. Figure 1 Patient ( A ) ulcerative lesions with massive purulent discharges in perianal area before abrocitinib treatment (Aa); extensive infiltration of lymphocytes and neutrophils and necrotising vasculitis (Ab, ×100); significant improvement of skin lesions 1 week after abrocitinib and cyclosporine A treatment (Ac) and 4 weeks after starting abrocitinib treatment (Ad). Patie -Abstract Truncated-
dermatology